Kiromic Biopharma

Kiromic Biopharma

  • Founded: 2012
  • Location: Houston, TX
  • Employee range: 50 - 200
  • Clinical stage: Clin0
  • Therapy area: NSCLC
  • Drug types: ONC
  • Lead product: Deltacel
  • Product link:
  • Funding: $15M IPO Oct 2020

job board

Short description:

Personalized CAR T Treatment

Drug notes:

Procel 2 efforts Clin0 oncology; Isocel 2 efforts Clin0 oncology

Long description:

Kiromic Biopharma is addressing solid tumors through the development of allogeneic gamma delta T-cell therapies. To develop these therapies Kiromic is using Diamond AI, a neural network of predictive analytics and machine learning synergistically designed to identify the best possible cancer therapy targets. This enables Kiromic to screen for new cancer targets from billions of data points, streamlining their approach to develop effective CAR-T therapies. In addition, Kiromic is lowering manufacturing costs through development of ABBIE, their non-viral, genetic engineering platform to offer a more precise approach to deliver their therapeutic proteins.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy